Zacks upgrades Medifast stock to Strong Buy ahead of October 26 results

Published on 10/20/2026 at 19:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 76.38 million, while net loss was USD 3.10 million for the quarter. Medifast stock costs EUR 10.67 on October 20, 2026.

Analyst rating and reporting date

Zacks Research upgraded Medifast from Hold to Strong Buy on October 13, 2026.
Second-quarter revenue reached USD 76.38 million and net loss was USD 3.10 million.
Medifast stock costs EUR 10.67 at Lang & Schwarz on October 20, 2026 at 7:06 p.m. CEST.
Medifast is scheduled to report third-quarter results before market open on October 26, 2026.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast (ISIN US58470H1014) was upgraded by Zacks Research from Hold to Strong Buy in a report dated October 13, 2026, as MarketBeat reported. The rating change is the clearest recent analyst signal for the Baltimore-based health and wellness company. Medifast was trading at EUR 10.67 at Lang & Schwarz on October 20, 2026 at 7:06 p.m. CEST.

Revenue remains the key test

Medifast reported USD 76.38 million of revenue for the second quarter ended June 30, 2026, alongside a net loss of USD 3.10 million. Revenue was down 27.60 percent from USD 105.50 million in the second quarter of 2025, while the loss narrowed from USD 4.70 million in the year-earlier period, according to the company release carried by Business Wire.

The same second-quarter release reported revenue per active earning coach of USD 6,529 and 11,700 independent active earning coaches. Those operating measures matter because the company is shifting its health and wellness offering toward the Trilivy metabolic health system.

October 26 is the next test

Medifast is scheduled to announce results for the third quarter ended September 30, 2026 before market open on October 26, 2026, with an earnings call at 8:30 a.m. ET. Business Wire gave the date and reporting period in its October 14, 2026 announcement.

MarketBeat cited consensus expectations of USD 71.30 million in third-quarter revenue and a USD 0.35 loss per share. That would represent a further USD 5.08 million decline from the second-quarter revenue figure, making customer growth and coach productivity important measures in the next report.

Price and valuation frame

Medifast had a market capitalization of USD 133.9 million on October 20, 2026. Its USD 9.22 to USD 13.45 52-week range places the current US share price inside a relatively narrow trading band, while the company profile identifies Medifast as a Consumer Cyclical business in Personal Products and Services.

Stock price after hours

The euro quotation stood at EUR 10.67 at Lang & Schwarz on October 20, 2026 at 7:06 p.m. CEST. The primary listing is on the NYSE, where the stock was last quoted at USD 11.98 on October 20, 2026 at 1:08 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Medifast stock.